Home / Themes / GLP-1 Long '24: Improved Looks
GLP-1 Long '24: Improved Looks (view performance)
Last updated
Theme thesis · 5/5 sections · Tickers 7 with notes · 5 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThe GLP-1 'Improved Looks' theme remains bullish, driven by increasing GLP-1 drug adoption leading to significant weight loss. This fuels demand for cosmetic en
Thesis
The GLP-1 'Improved Looks' theme remains bullish, driven by increasing GLP-1 drug adoption leading to significant weight loss. This fuels demand for cosmetic enhancements, updated fashion, and boosts confidence for social engagement, particularly in online dating, creating a broad tailwind for appearance-focused consumer sectors.
Bull case
Increased usage of GLP-1 drugs is driving demand for cosmetic surgeries, skin tightening, and related aesthetic products as individuals seek to address changes in appearance post-weight loss, benefiting the medical aesthetics sector.
Online dating platforms are experiencing higher user engagement and monetization as individuals, feeling more confident due to improved appearances from GLP-1 usage, actively seek new social connections and relationships.
Fashion retailers are seeing increased sales as consumers update their wardrobes to fit changing body sizes and embrace new styles post-weight loss, leading to a structural uplift in demand for apparel.
Bear case
The high cost of GLP-1 drugs and varying insurance coverage may limit widespread adoption, potentially dampening the expected surge in demand for appearance-related products and services.
Economic downturns, persistent inflation, or rising interest rates could reduce discretionary spending on non-essential consumer sectors like fashion, cosmetic procedures, and premium dating services, impacting theme growth.
Potential long-term side effects, health risks, or negative public perception associated with prolonged GLP-1 usage could lead to a decline in drug popularity, subsequently impacting related industries that benefit from the 'improved looks' trend.
Overview
Hiring Trend Watchpoints
Forum Watchlist
- Reddit — r/OzempicHigh
User experiences with weight loss, body changes, side effects, and impact on appearance/confidence.
- Reddit — r/PlasticSurgeryMedium
Discussions around 'Ozempic face,' skin tightening, and other aesthetic procedures post-GLP-1 weight loss.
- Reddit — r/DatingAppsHigh
User sentiment and engagement with dating platforms, especially related to confidence, new features (like Bumble's AI), and post-weight loss dating experiences.
- Reddit — r/PlusSizeFashionMedium
Discussions on changing body sizes, new wardrobe needs, and brand preferences (e.g., Torrid) as GLP-1 users transition.
- Industry Forum — MedSpa Owners ForumMedium
Clinic-level observations on demand for GLP-1-adjacent aesthetic treatments, pricing, and patient profiles.
Second Order Trends
Search Keywords Brand Product
- Ozempic
- Wegovy
- Mounjaro
- Zepbound
- Skyrizi
- Rinvoq
- Relfydess
- Sculptra
- Nemluvio
- Juvederm
- Botox Cosmetic
- AirSculpt Smooth
Search Keywords Policy Regulatory
- GLP-1 insurance coverage
- Medicare drug negotiation
- aesthetic procedure financing
Search Keywords Event Phrases
- Ozempic face treatment
- GLP-1 skin tightening
- post-weight loss fashion trends
- dating app confidence boost
- Torrid Casting Call
Google Trend Product Category Intent
Google Trend Consumer Intent
Google Trend Macro Policy Terms
Top datasets to track
1. IQVIA GLP-1 Prescription Data Type: Healthcare Data · Provider: IQVIA Cadence: Monthly Why it matters: Directly tracks the adoption rate and growth of GLP-1 drugs, which is the foundational driver of the 'Improved Looks' theme. Suggested query: GLP-1 prescription volume growth by drug and indication (weight loss) Confidence: High
2. SimilarWeb Dating App Engagement Metrics Type: Alternative Data · Provider: SimilarWeb Cadence: Monthly Why it matters: Measures user activity, downloads, and engagement on major dating platforms, signaling confidence and social interaction changes post-GLP-1 weight loss. Suggested query: Bumble app active users, session duration, and new downloads; overall dating app market share changes. Confidence: High
3. Credit Card Data - Apparel & Fashion Spending Type: Economic Data · Provider: Various (e.g., Facteus, Earnest Research) Cadence: Monthly Why it matters: Tracks changes in consumer spending on fashion retail, indicating if GLP-1 users are updating their wardrobes due to body changes. Suggested query: Growth in discretionary spending on apparel, specifically for brands catering to diverse sizing or fashion updates. Confidence: High
4. M Science Aesthetic Treatment Volume Tracker Type: Alternative Data · Provider: M Science Cadence: Quarterly Why it matters: Provides granular data on aesthetic procedure volumes, including facial fillers, skin tightening, and body contouring, directly signaling demand for GLP-1-adjacent treatments. Suggested query: Volume trends for facial fillers, biostimulators, and non-invasive body contouring procedures; specific mentions of GLP-1 patient segments. Confidence: High
5. SimilarWeb Torrid Website Traffic & Conversion Type: Alternative Data · Provider: SimilarWeb Cadence: Monthly Why it matters: Monitors Torrid's online customer acquisition, engagement, and conversion rates, crucial for tracking their 'customer file growth' strategy in a changing consumer landscape. Suggested query: Torrid.com unique visitors, bounce rate, conversion rate, and traffic sources. Confidence: Medium
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| GLP-1 Prescription Rates | Monthly | Indicates the adoption rate of GLP-1 drugs | Google_Sheets |
| User Engagement on Dating Platforms | Monthly | Measures activity and engagement on dating sites | Google_Sheets |
| Consumer Spending on Fashion | Monthly | Tracks changes in fashion retail sales | Google_Sheets |
Upcoming Catalysts
| Catalyst | Estimated Timing | Estimated Date Start | Estimated Date End | Why It Matters | Ticker Or Theme Specific | Source Types | Contributing Tickers | Mention Count | Base Score | Source Weight | Specificity Weight | Macro Bridge | Macro Bridge Multiplier | Theme Score | Date Aggregated | Manual Override | Bridge Mention Count | Theme Base Score | Theme Importance Score | Catalyst Source | Catalyst ID | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emergence of definitive studies or explicit company commentary from aesthetic providers (e.g., Galderma, AirSculpt) quantifying the 'GLP-1 aesthetics tailwind' and incremental spending by GLP-1 users on aesthetic treatments. | Ongoing, with potential for new reports or commentary in H2 2026. | 2026-07-01 | 2026-12-31 | This would provide strong validation for a core bullish thesis point, directly impacting aesthetic companies by confirming a new, structural demand driver for fillers, biostimulators, skin tightening, and body contouring procedures among GLP-1 users. | Theme | theme_composer | GALD.SW, AIRS, ABBV | 3 | 0.0117 | 1.18 | 0.92 | 1.0 | 1.272 | 2026-06-13 | False | 1 | 0.5037 | 54.6764 | Theme composer | ||||
| Bumble's (BMBL) full launch of its AI-first cloud-native Bumble 2.0 platform and the public beta release of its 'b' AI assistant, designed to enhance user experience and matchmaking. | Q2 2026 (by June 30, 2026) for Bumble 2.0, with the 'b' AI assistant public beta expected soon after, potentially rolling out in select markets in Q4 2026. | 2026-06-13 | 2026-12-31 | A successful launch could significantly boost user engagement and payer penetration on Bumble's platform by addressing 'swipe fatigue' and offering more personalized connections. This directly benefits the online dating segment of the 'Improved Looks' theme as users feel more confident post-GLP-1 weight loss. | Ticker | theme_composer | BMBL | 1 | 0.0 | 1.18 | 0.92 | 1.0 | 0.0006 | 2026-06-13 | False | 1 | 0.0001 | 0.0066 | Theme composer | ||||
| US regulatory approval decision for SKYRIZI subcutaneous induction dosing option in Crohn's disease. | later this fall | 2026-09-01 | 2026-11-30 | This approval would provide a convenient subcutaneous induction option for Crohn's patients, supported by strong efficacy data, which is expected to accelerate SKYRIZI's capture rate in the IBD market. | Ticker | ABBV (ticker) | ABBV_f4ed1dbb | 2026-07-31 | earnings_transcript | ||||||||||||||
| FDA approval decision for tevapadone, a novel selective D1/D5 dopamine agonist, for Parkinson's disease. | third quarter | 2026-07-01 | 2026-09-30 | This approval would enable the launch of a new, highly effective treatment for motor symptoms in Parkinson's, contributing significantly to AbbVie's neuroscience portfolio and its projected $5 billion peak sales for the Parkinson's franchise. | Ticker | ABBV (ticker) | ABBV_b765bcfd | 2026-07-31 | earnings_transcript | ||||||||||||||
| Data from two additional cohorts of a Phase 2 study evaluating bradicilacin in major depressive disorder (MDD). | by Q3 or so | 2026-07-01 | 2026-09-30 | This data will inform the development strategy and Phase 3 plans, with bradicilacin having the potential to be a groundbreaking new treatment in depression due to its strong efficacy and short-acting profile. | Ticker | ABBV (ticker) | ABBV_ced91140 | 2026-02-04 | earnings_transcript | ||||||||||||||
| US commercial approval decision for tevapadon in Parkinson's disease. | an approval decision is anticipated in the third quarter for tevapadon in Parkinson's disease. | 2026-07-01 | 2026-09-30 | Approval would add a new, potentially multibillion-dollar asset to AbbVie's neuroscience portfolio, offering a new treatment option for Parkinson's disease. | Ticker | ABBV (ticker) | ABBV_800b4101 | 2026-02-04 | earnings_transcript | ||||||||||||||
| Data readout from Phase 3 studies evaluating QLIPTA and UBRELVY for menstrual migraine prevention. | data from both trials expected in the second half of this year. | 2026-07-01 | 2026-12-31 | Positive data could lead to label expansions for these leading migraine products, addressing a distinct and difficult-to-treat subtype of migraine and further driving sales. | Ticker | ABBV (ticker) | ABBV_47f622ef | 2026-02-04 | earnings_transcript | ||||||||||||||
| Initial rollout and patient treatment with AlloClae in select centers, a structural adipose tissue allograft for non-surgical body contouring. | later this quarter | 2026-08-11 | 2026-09-30 | This partnership expands AirSculpt's addressable market by serving patients without enough fat for traditional transfers and capitalizes on growing interest in targeted volume restoration, particularly among GLP-1 users, with expected accretive gross margin dollars. | Ticker | AIRS (ticker) | AIRS_c990eec4 | 2026-08-10 | earnings_transcript | ||||||||||||||
| Introduction of new Bumble BFF functionalities, including group discovery and features to facilitate curated, real-world social settings, extending into group dating. | a series of product updates planned as fast follows, including the introduction of functionality designed to bring members together in curated, real-world settings. | 2026-07-01 | 2026-12-31 | This initiative targets Gen Z's social preferences, aiming to deepen engagement within BFF and create new pathways into Bumble Date, potentially expanding the user base and increasing overall platform activity. Successful adoption is bullish. | Ticker | BMBL (ticker) | BMBL_46d0cf30 | 2026-03-11 | earnings_transcript | ||||||||||||||
| Moderation of year-over-year revenue declines and sequential stabilization/improvement in key operating metrics like active users and payers. | As we move through 2026, we expect our revenue headwinds to moderate as the impacts of recent trends in our operating metrics flow through the financials. | 2026-04-01 | 2026-12-31 | This is a critical indicator of the success of Bumble's quality reset and product innovation strategy, signaling a potential return to growth and a positive shift in investor sentiment. Achievement is bullish, continued declines are bearish. | Ticker | BMBL (ticker) | BMBL_50fb7f11 | 2026-03-11 | earnings_transcript | ||||||||||||||
| Launch of two new bras within the Curve intimate apparel brand. | in the back half of the year | 2026-07-01 | 2026-12-31 | Bras are a key product category that drives strong customer acquisition, reactivation, and long-term loyalty, potentially boosting sales and customer engagement in the intimate apparel segment. | Ticker | CURV (ticker) | CURV_ae4fe6f9 | 2026-03-19 | earnings_transcript | ||||||||||||||
| Full reintroduction and scaling of the footwear business, including the launch of the boot business in Q3, shifting from a first-half headwind to a second-half positive impact. | positive impact in the second half of the year | 2026-06-01 | 2026-12-31 | This is expected to recapture lost direct revenue and attachment-driven sales, driving stronger attachment rates, improved profitability, and a positive comparable sales impact in the second half of 2026. | Ticker | CURV (ticker) | CURV_94d63ed7 | 2026-03-19 | earnings_transcript | ||||||||||||||
| Rollout and expansion of new fleece programs and knit dressing capsule collections. | in the back half of the year | 2026-07-01 | 2026-12-31 | These new product offerings are expected to be advantageous and contribute to sales growth, particularly in the back half of the year, by expanding the product assortment. | Ticker | CURV (ticker) | CURV_9cd7ebbc | 2026-03-19 | earnings_transcript | ||||||||||||||
| The footwear program, which was a headwind in the first half due to restructuring, is expected to resolve and return to full strength. | second half of the year | 2026-07-01 | 2026-12-31 | This is anticipated to become a tailwind for comparable sales in the second half, providing a sizable benefit and historically enhancing attachment rates and overall customer spend. A successful return is bullish for sales and customer engagement, while delays or underperformance would be bearish. | Ticker | CURV (ticker) | CURV_36938b6a | 2026-06-04 | earnings_transcript | ||||||||||||||
| Successful execution of targeted marketing strategies to acquire new customers, reactivate lapsed ones, and deepen loyalty and purchase frequency of existing customers. | in 2026 | 2026-01-01 | 2026-12-31 | This is the company's primary focus for 2026, expected to drive future sales and long-term value creation. Growth in the customer file is bullish, while stagnation or decline would be bearish. | Ticker | CURV (ticker) | CURV_b24ee74c | 2026-06-04 | earnings_transcript | ||||||||||||||
| The relaunch of an expanded, year-round Casting Call platform, including a Times Square activation, mall events, and in-store parties, culminating in a winner announcement in November. | relaunching an expanded reconceived casting call in July | 2026-07-01 | 2026-11-30 | Casting Call is a key platform designed to drive customer acquisition, reactivation, and retention, and has historically increased brand awareness. Successful execution is bullish for customer file growth and brand engagement. | Ticker | CURV (ticker) | CURV_94f36efe | 2026-06-04 | earnings_transcript | ||||||||||||||
| Recovery of additional tariff refunds from the first phase ($9-$11 million) and a forthcoming second phase ($1.5-$2.5 million). | additional recoveries expected as the claims process progresses | 2026-06-01 | 2026-12-31 | These refunds are not included in current guidance and represent a potential upside of $10.5 million to $13.5 million, which would positively impact profitability. | Ticker | CURV (ticker) | CURV_f56e7b72 | 2026-06-04 | earnings_transcript | ||||||||||||||
| The actual tariff rate applied to goods in the second half of fiscal 2026. Guidance assumes a step-up to 15% from 10%. | for the second half | 2026-07-01 | 2026-12-31 | If tariffs remain at 10% for the full year, it would offset potential freight-related headwinds, which would be bullish for margins. An escalation beyond 15% or worse-than-expected freight headwinds would be bearish. | Ticker | CURV (ticker) | CURV_f5e82e96 | 2026-06-04 | earnings_transcript | ||||||||||||||
| Tinder's 'Events' feature is planned to expand its availability to 26 cities across the US and Europe. | by the end of September | 2026-09-01 | 2026-09-30 | This expansion aims to drive reconsideration and new user acquisition, particularly among Gen Z, by offering social, lower-pressure ways to connect in real life, potentially shifting Tinder's brand perception and increasing MAUs. | Ticker | MTCH (ticker) | MTCH_6584f3e8 | 2026-08-04 | earnings_transcript | ||||||||||||||
| Tinder's Daily Active Users (DAU) are expected to turn positive year-over-year. | any day now | 2026-08-01 | 2026-09-30 | This is a significant milestone for Tinder, marking the first time in over three years that the app has achieved positive year-over-year usage, indicating improved product experience and user engagement, which is crucial for future MAU and revenue growth. | Ticker | MTCH (ticker) | MTCH_e84041f2 | 2026-08-04 | earnings_transcript | ||||||||||||||
| US regulatory approval decision for RINVOQ for the treatment of vitiligo. | later this year | 2026-10-01 | 2026-12-31 | This approval would mark RINVOQ as the first systemic treatment for vitiligo, significantly expanding its market potential and contributing to the anticipated combined peak sales of $2 billion for vitiligo and alopecia areata indications. | Ticker | ABBV (ticker) | ABBV_c5da1469 | 2026-07-31 | earnings_transcript | ||||||||||||||
| Opening of 7 new Life Time clubs. | in the fourth quarter | 2026-10-01 | 2026-12-31 | These new club openings are expected to contribute significantly to the company's revenue and adjusted EBITDA growth for late 2026 and into 2027. | Ticker | LTH (ticker) | LTH_38700d4e | 2026-07-30 | earnings_transcript |
NotesEarnings Summary
| Date | Type | Comment | Detail | Sentiment | Tickers |
|---|---|---|---|---|---|
| 2026-06-13 | Theme Update | The GLP-1 Long '24: Improved Looks theme is reinforced by CURV's strategic focus on accelerating customer file growth and expanding sub-brands. While CURV's earnings didn't explicitly cite GLP-1s, its initiatives to capture new and reactivated customers for wardrobe updates align with the theme's premise of increased fashion spending post-weight loss. This suggests continued underlying demand in related consumer sectors, supported by efficient marketing. | Earnings Summary | Bullish | CURV |
Constituents
- ABBVT3— AbbVie Inc.
- AIRST3— AirSculpt Technologies, Inc.
- BMBLT3— Bumble Inc.
- CURVT3— Torrid Holdings Inc.
- GALD.SWT3— Galderma Group AG
- LTHT3— Life Time Group Holdings, Inc.
- MTCHT3— Match Group, Inc.
- APYXT3· no notes yet
- EOLST3· no notes yet
- ESTAT3· no notes yet
- GRNDT3· no notes yet
- XPOFT3· no notes yet